Press Trust Of India / New Delhi/Basel (Switzerland) Sep 04, 2009, 01:27 IST
Swiss drug maker Novartis today said its newly developed vaccine ‘Celtura’ against Influenza A H1N1 (swine flu) has shown effective result during a pilot test conducted by it.
The test, done on 100 healthy volunteers aged between 18 and 50 by Leicester University of Britain, has shown a protective immune response in the case of 80 per cent of the volunteers, administered with a single dose of the vaccine, Novartis said in a statement.
The response in case of volunteers having two doses of vaccines was more than 90 per cent, it added.
“The pilot results are encouraging,” Novartis’ CEO, Vaccines and Diagnostics, Andrin Oswald said, adding, “The study suggests that while two doses seem to provide better protection, one dose of our adjuvanted Celtura vaccine may be sufficient to protect adults against the swine flu.”
According to industry experts, a vaccine response of above 60 per cent can be termed as successful and has the potential to hit the market soon.
The Swiss drug maker also said more trials involving 6,000 volunteers, including children, are already under way.
However, the company has not provided details about the availability of vaccine in the market.
Prison Planet.com
September 2, 2009
The Centers for Disease Control and Prevention asked neurologists to report cases of Guillain-Barre syndrome, it causes paralysis and breathing difficulties and is sometimes fatal. It also weakens limbs! The swine flu vaccine is being rushed through safety procedures and governments have provided pharmaceutical companies with blanket immunity from lawsuits arriving out of the vaccine causing deaths and injuries.It was revealed some batches of the vaccine contain mercury, a toxin linked with autism and neurological disorders. The vaccine also contains the ingredient squalene and a host of other debilitating diseases.Surveys show multitudes of health professionals refuse to take the vaccine!
Content Guide
